These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 9572853

  • 1. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.
    Egelund R, Rodenburg KW, Andreasen PA, Rasmussen MS, Guldberg RE, Petersen TE.
    Biochemistry; 1998 May 05; 37(18):6375-9. PubMed ID: 9572853
    [Abstract] [Full Text] [Related]

  • 2. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R, Petersen TE, Andreasen PA.
    Eur J Biochem; 2001 Feb 05; 268(3):673-85. PubMed ID: 11168406
    [Abstract] [Full Text] [Related]

  • 3. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.
    Aertgeerts K, De Ranter CJ, Booth NA, Declerck PJ.
    J Struct Biol; 1997 Apr 05; 118(3):236-42. PubMed ID: 9169233
    [Abstract] [Full Text] [Related]

  • 4. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
    Turner PC, Baquero MT, Yuan S, Thoennes SR, Moyer RW.
    Virology; 2000 Jul 05; 272(2):267-80. PubMed ID: 10873770
    [Abstract] [Full Text] [Related]

  • 5. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.
    FEBS J; 2006 Nov 05; 273(22):5143-59. PubMed ID: 17042782
    [Abstract] [Full Text] [Related]

  • 6. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A, Knockaert I, Declerck PJ.
    Biochemistry; 1996 Jun 11; 35(23):7474-81. PubMed ID: 8652525
    [Abstract] [Full Text] [Related]

  • 7. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM, Petersen HH, Jacobsen C, Moestrup SK, Etzerodt M, Andreasen PA, Thøgersen HC.
    Biochem J; 2001 Jul 01; 357(Pt 1):289-96. PubMed ID: 11415462
    [Abstract] [Full Text] [Related]

  • 8. Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.
    Jankun J, Specht Z, Szkudlarek M, Greenfield R, Gaikwad B, Trifonov L, Vaugeois J, Aleem AM, Basrur V, Selman SH, Zavodszky MI, Skrzypczak-Jankun E.
    Int J Mol Med; 2006 Mar 01; 17(3):437-47. PubMed ID: 16465390
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO, Verhamme I, Shore JD.
    Biochemistry; 1998 Nov 03; 37(44):15491-502. PubMed ID: 9799512
    [Abstract] [Full Text] [Related]

  • 10. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.
    Wind T, Hansen M, Jensen JK, Andreasen PA.
    Biol Chem; 2002 Jan 03; 383(1):21-36. PubMed ID: 11928815
    [Abstract] [Full Text] [Related]

  • 11. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA.
    Eur J Biochem; 1997 Sep 15; 248(3):775-85. PubMed ID: 9342229
    [Abstract] [Full Text] [Related]

  • 12. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q, Shaltiel S.
    BMC Biochem; 2003 Jul 08; 4():5. PubMed ID: 12848892
    [Abstract] [Full Text] [Related]

  • 13. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
    Rezaie AR.
    Biochemistry; 1998 Sep 22; 37(38):13138-42. PubMed ID: 9748320
    [Abstract] [Full Text] [Related]

  • 14. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J, Aleem AM, Selman SH, Basrur V, Skrzypczak-Jankun E.
    Int J Mol Med; 2009 Jan 22; 23(1):57-63. PubMed ID: 19082507
    [Abstract] [Full Text] [Related]

  • 15. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
    Stoop AA, Jespers L, Lasters I, Eldering E, Pannekoek H.
    J Mol Biol; 2000 Sep 01; 301(5):1135-47. PubMed ID: 10966811
    [Abstract] [Full Text] [Related]

  • 16. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot AJ, van Tienoven DT, Beex LV, Sweep FC.
    Thromb Haemost; 2004 Mar 01; 91(3):514-21. PubMed ID: 14983227
    [Abstract] [Full Text] [Related]

  • 17. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J.
    Mol Cancer Ther; 2003 Jan 01; 2(1):19-28. PubMed ID: 12533669
    [Abstract] [Full Text] [Related]

  • 18. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B, Verbeke K, Compernolle G, Biesemans W, Gils A, Declerck PJ.
    Biochem Biophys Res Commun; 2003 Aug 01; 307(3):529-34. PubMed ID: 12893254
    [Abstract] [Full Text] [Related]

  • 19. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
    Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ.
    J Mol Biol; 2000 Mar 31; 297(3):683-95. PubMed ID: 10731421
    [Abstract] [Full Text] [Related]

  • 20. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA, Elrod K, Luong C, Rice MJ, Mackman RL, Sprengeler PA, Spencer J, Hataye J, Janc J, Link J, Litvak J, Rai R, Rice K, Sideris S, Verner E, Young W.
    J Mol Biol; 2001 Apr 13; 307(5):1451-86. PubMed ID: 11292354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.